Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension of JM-010 in Parkinson's Disease Dyskinesia
NCT05516875Phase 2Terminated
- Sponsor
- Contera Pharma
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of JM-010 in levodopa-induced dyskinesia (LID), sponsored by Contera Pharma. Started Jan 2024; status: terminated.
02
Drugs
JM-010
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT05516875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516875.